X4 Pharmaceuticals (XFOR) & Its Rivals Head-To-Head Review

X4 Pharmaceuticals (NASDAQ:XFOR) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare X4 Pharmaceuticals to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Valuation & Earnings

This table compares X4 Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11 million	-$79.20 million	-4.75
X4 Pharmaceuticals Competitors	$727.18 million	$12.84 million	-15.18

X4 Pharmaceuticals’ rivals have higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and price targets for X4 Pharmaceuticals and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1	1	4	0	2.50
X4 Pharmaceuticals Competitors	9839	15124	45438	1588	2.54

X4 Pharmaceuticals currently has a consensus target price of $11.25, suggesting a potential upside of 253.77%. As a group, “Biotechnology” companies have a potential upside of 102.87%. Given X4 Pharmaceuticals’ higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares X4 Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-474.74%	-49.62%	-30.80%
X4 Pharmaceuticals Competitors	-12,346.73%	-197.60%	-30.56%

Insider and Institutional Ownership

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

X4 Pharmaceuticals has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals’ rivals have a beta of 1.10, indicating that their average stock price is 10% more volatile than the S&P 500.

Summary

X4 Pharmaceuticals rivals beat X4 Pharmaceuticals on 7 of the 13 factors compared.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.